NM Merchantiles Limited Increases Stake in IOL Chemicals to 17.08% Through Merger Acquisition

NM Merchantiles Limited has announced a significant acquisition of equity shares in IOL Chemicals and Pharmaceuticals Limited through a regulatory disclosure filed under SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. The acquisition was completed through a merger transaction that transferred substantial shareholding from Vasudeva Commercials Limited. Acquisition Details The transaction involved the acquisition of 1,17,41,100 equity shares of IOL Chemicals and Pharmaceuticals Limited, representing a 4.00% increase in both total share capital and voting rights. The shares were transferred under a merger scheme approved by the Hon'ble Regional Director (NR) New Delhi through Order Numbers RDNR/233/AC1499296/2026/14531 and RDNR/233/AC1499296/2026/14530 dated 12.02.2026. Parameter Before Acquisition Acquired Shares After Acquisition Number of Shares 3,83,90,550 1,17,41,100 5,01,31,650 Percentage Holding 13.08% 4.00% 17.08% Voting Rights 13.08% 4.00% 17.08% Merger Transaction Structure The acquisition was executed through the merger of Vasudeva Commercials Limited with NM Merchantiles Limited. The shares of IOL Chemicals and Pharmaceuticals Limited previously held by Vasudeva Commercials were transferred to NM Merchantiles' account as part of this corporate restructuring. The effective date of share transfer was 05th March 2026. Company Information Detail Information Target Company IOL Chemicals and Pharmaceuticals Limited Acquirer Status Promoter/Promoter Group Stock Exchanges National Stock Exchange, BSE Limited Share Capital Rs. 58,70,55,020 (29,35,27,510 shares of Rs. 2 each) Regulatory Compliance The disclosure was made in compliance with Regulation 29(2) of SEBI (Substantial Acquisition of Shares and Takeover) Regulations, 2011. NM Merchantiles Limited, formerly known as NM Merchantiles Private Limited, filed the necessary documentation with both the National Stock Exchange and BSE Limited, where IOL Chemicals and Pharmaceuticals Limited shares are listed. The transaction maintains the total equity share capital of IOL Chemicals and Pharmaceuticals Limited at Rs. 58,70,55,020, comprising 29,35,27,510 equity shares of Rs. 2 each. The acquisition strengthens NM Merchantiles' position as a promoter group entity in the target company, with no changes to the overall share capital structure of IOL Chemicals and Pharmaceuticals Limited. IOL Chemicals & Pharmaceuticals has secured an important regulatory milestone with the European Directorate for the Quality of Medicines & Health Care (EDQM) granting a Certificate of Suitability (CEP) for its API product Metformin Hydrochloride Process-II. This achievement expands the company's regulatory portfolio for this critical antidiabetic medication. Regulatory Certification Details The EDQM certification represents a significant regulatory approval for IOL Chemicals & Pharmaceuticals' manufacturing processes. The company disclosed that this new CEP comes in addition to an existing valid certificate already held for Metformin Hydrochloride, indicating the company now has multiple approved processes for manufacturing this important pharmaceutical ingredient. Parameter: Details Certification Body: European Directorate for the Quality of Medicines & Health Care (EDQM) Product: Metformin Hydrochloride Process-II Certificate Type: Certificate of Suitability (CEP) Additional Certification: Existing valid CEP for Metformin Hydrochloride Product Significance Metformin Hydrochloride serves as a crucial antidiabetic drug used to manage high blood sugar levels in diabetes patients. The availability of multiple certified manufacturing processes for this API demonstrates IOL Chemicals & Pharmaceuticals' commitment to ensuring reliable supply and manufacturing flexibility for this essential medication. Regulatory Compliance The company announced this development in compliance with Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The disclosure ensures transparency with stakeholders and regulatory authorities regarding this significant regulatory achievement. Strategic Impact This additional EDQM certification strengthens IOL Chemicals & Pharmaceuticals' position in the pharmaceutical API market, particularly for diabetes management medications. Having multiple approved processes for Metformin Hydrochloride production provides the company with enhanced manufacturing capabilities and regulatory compliance across European markets. We’re building Scanx - to help you express your trading & investing idea, to help you analyse the markets better. Stock Markets are the true indicator of the growth of any country's economy. We are bullish on India, we are bullish on India's prospects to be one of largest economies of the world. We believe that Stock Markets provide an unique opportunity for all Indians to participate in the growth story of India. We are enabling the same for Indians. As financial services are becoming more accessible, there is now a large set of Indians today who are financially aware and literate. They value time and seek high quality products & services. Most screening, trading, investing platforms available today are more or less similar to each other, and they have not evolved with time. While both traders & investors have gotten smart about how they make money and build wealth, as users they have continued to use the same products, features, and platforms that were available for years with little or no innovation. We plan to change that - a technology-led platform built for super traders and long term investors.